1075PPhase I study of CC-90010 in patients with advanced solid tumours and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)

ConclusionsMost TRAEs were mild or moderate in severity and manageable with dose modifications. CC-90010 had a long terminal half-life that enabled less frequent dosing and promising anticancer activity. Dose escalation is complete, and expansion in select advanced malignancies is ongoing. Table: 1075PDose Level:1 (n  = 7)2 (n = 7)3A (n = 4)3B (n = 6)3C (n = 6)4A (n = 7)4B (n = 7)4C (n = 7)5A (n = 6)5B (n = 6)5C (n = 6)Dose, mg1515253015404525305535Schedule, days on/off3/43/113/114/242/53/114/242/53/114/242/5Clinical trial identificationNCT03220347; 2015-004371-79.Editorial acknowledgementTisheeka Graham-Steed, PhD BioConnections, LLC.Legal entity responsible for the studyCelgene Corporation.FundingCelgene Corporation.DisclosureV. Moreno: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: BMS; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Regeneron; Speaker Bureau / Expert testimony: Bayer/Loxo. I. Brana: Research grant / Funding (self): Celgene. J.M. Sepulveda Sanchez: Advisory / Consultancy, Research grant / Funding (self): Pfizer; Advisory / Consultancy, Travel / Accommodation / Expenses: AbbVie; Advisory / Consultancy: Celgene; Advisory / Consultancy: GW Pharma; Speaker Bureau / Expert testimony: Astellas; Travel / Accommodation / Expenses: Ipsen. M. Vieito Villar: Travel / Accommodation / Expenses: Roche. O. Saavedra: Travel / Accommodation / Expenses: Mundiphar...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research